Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism, and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism.

Biotechnology

Health & Wellness

Health Care

Pharmaceutical

Amolyt Pharma

Thierry Abribat

Niccole Larsen, PhD

michel ovize

Blandine WEISS

Taha Ould Rouis, MD

Caroline Robo (Fesquet)

Patrick Loustau

Michael Culler

Lou Arcudi

Laetitia Ouafki

Héloïse Boullet

Guillaume Ravel, PharmD, PhD, DABT

Delphine Martinez

Damien Aumaille

Clémentine Chalmey

Aurélie MILLERAT

The Finance Team at Amolyt Pharma manages the company's financial health, overseeing budgeting, financial planning, and analysis. They handle accounting, ensure regulatory compliance, and provide strategic insights to support the development of peptide treatments for rare endocrine and metabolic disorders.

Finance Team

Clinical Management Team

Leadership Team

CMC Team

Finance Team

About

Team members

Other teams at Amolyt Pharma

Clinical Management Team

Leadership Team

CMC Team